Table 1. Study Groups, Mean Ages, Vascular Endothelial Growth Factor, Prostate-Specific Antigen, and Prostate Volume Values a, b.
Control | BPH | Cancer | P value | |
---|---|---|---|---|
Age, y | 67.2 ± 7.2 | 68.7 ± 8.3 | 66.5 ± 9.1 | 0.38 |
40-59 | 7 (12.3) | 6 (10.5) | 9 (20.5) | |
60-69 | 26 (45.6) | 25 (43.9) | 24 (54.5) | |
≥ 70 | 24 (42.1) | 26 (45.6) | 11 (25) | |
VEGF, pg/mL | 124.9 ± 50.8 | 147.5 ± 80 | 356.3 ± 181.1 | < 0.001 |
PSA, ng/mL | 1.94 ± 1.94 | 3.86 ± 2.3 | 38.7 ± 17.5 | < 0.001 |
Prostate volume | 37.4 ± 15.5 | 71.7 ± 25.5 | < 0.001 |
a Abbreviations: BPH, benign prostate hyperplasia; PSA, prostate-specific antigen; VEGF, vascular endothelial growth factor.
bData are presented as mean ± SD or No. (%).